Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 2
2004 1
2006 1
2007 1
2008 1
2011 1
2015 3
2017 1
2019 1
2020 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for raf boyle
Your search for Raf Buyle retrieved no results
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial.
Paradoxical activation of Raf by a novel Raf inhibitor.
Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P. Hall-Jackson CA, et al. Chem Biol. 1999 Aug;6(8):559-68. doi: 10.1016/s1074-5521(99)80088-x. Chem Biol. 1999. PMID: 10421767
These observations imply that some agonists reported to trigger the cellular activation of c-Raf might actually be inhibitors of this enzyme, and that compounds which inhibit the kinase activity of Raf might not be useful as anticancer drugs. The binding sites for Z …
These observations imply that some agonists reported to trigger the cellular activation of c-Raf might actually be inhibitors of this …
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.
Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ. Young A, et al. Cancer Res. 2017 Sep 1;77(17):4684-4696. doi: 10.1158/0008-5472.CAN-17-0393. Epub 2017 Jun 26. Cancer Res. 2017. PMID: 28652244
The structural conformation of the tachykinin domain drives the anti-tumoural activity of an octopus peptide in melanoma BRAFV600E.
Moral-Sanz J, Fernandez-Rojo MA, Colmenarejo G, Kurdyukov S, Brust A, Ragnarsson L, Andersson Å, Vila SF, Cabezas-Sainz P, Wilhelm P, Vela-Sebastián A, Fernández-Carrasco I, Chin YKY, López-Mancheño Y, Smallwood TB, Clark RJ, Fry BG, King GF, Ramm GA, Alewood PF, Lewis RJ, Mulvenna JP, Boyle GM, Sanchez LE, Neely GG, Miles JJ, Ikonomopoulou MP. Moral-Sanz J, et al. Br J Pharmacol. 2022 Oct;179(20):4878-4896. doi: 10.1111/bph.15923. Epub 2022 Jul 29. Br J Pharmacol. 2022. PMID: 35818835 Free article.
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
Boyle TA, Quinn GP, Schabath MB, Muñoz-Antonia T, Saller JJ, Duarte LF, Hair LS, Teer JK, Chiang DY, Leary R, Wong CC, Savchenko A, Singh AP, Charette L, Mendell K, Gorgun G, Antonia SJ, Chiappori AA, Creelan BC, Gray JE, Haura EB. Boyle TA, et al. Cancer Med. 2020 Jan;9(1):225-237. doi: 10.1002/cam4.2670. Epub 2019 Nov 20. Cancer Med. 2020. PMID: 31747139 Free PMC article.
Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells.
Cheng G, Hardy M, Zielonka J, Weh K, Zielonka M, Boyle KA, Abu Eid M, McAllister D, Bennett B, Kresty LA, Dwinell MB, Kalyanaraman B. Cheng G, et al. Cancer Treat Res Commun. 2020;25:100210. doi: 10.1016/j.ctarc.2020.100210. Epub 2020 Sep 17. Cancer Treat Res Commun. 2020. PMID: 32987287 Free PMC article.
INTRODUCTION: Melanoma is an aggressive form of skin cancer for which there are no effective drugs for prolonged treatment. The existing kinase inhibitor antiglycolytic drugs (B-Raf serine/threonine kinase or BRAF inhibitors) are effective for a short time followed by a ra …
INTRODUCTION: Melanoma is an aggressive form of skin cancer for which there are no effective drugs for prolonged treatment. The existing kin …
BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Boyle EM, Ashby C, Tytarenko RG, Deshpande S, Wang H, Wang Y, Rosenthal A, Sawyer J, Tian E, Flynt E, Hoering A, Johnson SK, Rutherford MW, Wardell CP, Bauer MA, Dumontet C, Facon T, Thanendrarajan S, Schinke CD, Zangari M, van Rhee F, Barlogie B, Cairns D, Jackson G, Thakurta A, Davies FE, Morgan GJ, Walker BA. Boyle EM, et al. Clin Cancer Res. 2020 May 15;26(10):2422-2432. doi: 10.1158/1078-0432.CCR-19-1507. Epub 2020 Jan 27. Clin Cancer Res. 2020. PMID: 31988198 Free article.
Jun N-terminal kinase in rheumatoid arthritis.
Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Han Z, et al. J Pharmacol Exp Ther. 1999 Oct;291(1):124-30. J Pharmacol Exp Ther. 1999. PMID: 10490895
Low concentrations of SB 203580 (1 microM, a concentration that only inhibits p38) had no significant effect on IL-1-induced collagenase expression in RA FLS whereas 25 microM (which inhibits p38, JNK2, and c-raf) blocked collagenase mRNA accumulation. IL-1-stimulated AP-1 …
Low concentrations of SB 203580 (1 microM, a concentration that only inhibits p38) had no significant effect on IL-1-induced collagenase exp …
miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.
Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons J, Lanagan CM, Schmidt CW, Herington AC, Ballotti R, Pollock PM, Hayward NK. Stark MS, et al. Oncotarget. 2015 Jul 10;6(19):17753-63. doi: 10.18632/oncotarget.3924. Oncotarget. 2015. PMID: 25980496 Free PMC article.
These data provide another mechanism for the dysregulation of the MAPK pathway which may contribute to the profound resistance associated with current RAF-targeted therapies....
These data provide another mechanism for the dysregulation of the MAPK pathway which may contribute to the profound resistance associated wi …
15 results